Founded in Zurich in 2002, Lipideon Biotechnology AG focuses on developing a new class of non-absorbable drugs that inhibit cholesterol absorption in the small intestine, leading to reduced serum cholesterol levels. By targeting dyslipidemia, the main cause of arteriosclerosis, Lipideon aims to provide safer and improved treatment options. With arteriosclerosis affecting over 50% of the population in Western industrialized nations, the market potential for cholesterol-lowering drugs is significant. Lipideon's approach of using non-absorbable drugs minimizes or eliminates severe side effects by keeping the inhibitors in the small intestine rather than entering the circulatory system. Their research and development activities rely on synthetic organic chemistry, in-vitro assays, and animal model systems. Based in Zurich, Switzerland, the company was founded in 2002.